Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06086340 · ClinicalTrials.gov registry record
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 779
- Enrollment target
NCT06086340: Completed study, sponsored by Pfizer.
NCT06086340 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 779 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06086340 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 779 participants
- Enrollment target
Study Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States
Primary Outcome
Overall survival was defined as time in months from the study index date to all cause death. Study index date in this outcome measure was the date of first line of treatment initiation with palbociclib + AI or AI alone after the de novo mBC diagnosis. De novo mBC referred to breast cancer that physician diagnosed for the first time after it had already spread outside of the breast to distant parts of the body. Unadjusted analysis: analysis not considering any covariates, specifically potential d
Interventions
- DRUG Palbociclib
- DRUG Aromatase Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 779 participants |
| Start Date | 2023-09-29 |
| Est. Completion | 2024-01-24 |
What the finished NCT06086340 record still lists
NCT06086340 is an observational study that tracks outcomes without assigning an intervention. The registered 779 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Palbociclib is the first listed.
NCT06086340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06086340 about?
NCT06086340 is a clinical study titled "Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.". A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed h...
What is the current status of trial NCT06086340?
This trial is currently completed. The enrollment target is 779 participants. The study started on 2023-09-29. Estimated completion is 2024-01-24.
What interventions are being tested in trial NCT06086340?
The interventions under investigation include: Palbociclib (DRUG), Aromatase Inhibitor (DRUG).
Who is sponsoring clinical trial NCT06086340?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- NCT05513872 · 780 participants · Phase 1
Overcoming Nicotine Dependence to Enable Quitting
- NCT06310031 · 780 participants · NA
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI